BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Becton, Dickinson and Company (BDX) Release: New Influenza Test Offers Labs Advanced Performance and Reliable Results


9/21/2012 11:16:12 AM

FRANKLIN LAKES, N.J., Sept. 20, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD Veritor System for Rapid Detection of Flu A+B. This new product is cleared for use in clinical settings.

The new BD Veritor System for Rapid Detection of Flu A+B laboratory kit is specifically configured for testing liquid specimens obtained via nasopharyngeal wash, aspirate or swab in transport media. The system, with proprietary technologies, eliminates the subjective result interpretation of visually read assays and helps deliver an accurate read by providing reliable, objective results on a hand held reader with an easy-to-read digital display. The BD Veritor System for Rapid Detection of Flu A + B has demonstrated proven performance versus polymerase chain reaction tests (PCR). This is the only rapid diagnostic flu test that has been referenced and FDA cleared against this high-sensitivity standard.

"Visually read rapid flu tests have shown variable performance results and are prone to errors when interpreting results," said Tom Polen, President, BD Diagnostics Diagnostic Systems. "The BD Veritor System provides an advanced rapid diagnostic test for influenza A+B by offering accuracy, consistency, and convenience along with an objective read that laboratorians can trust."

The BD Veritor System utilizes Advanced Particle and Adaptive Read Technologies coupled with a special hand-held reader. The Advanced Particle Technology along with improved chemistries helps increase the sensitivity of the test. The Adaptive Read Technology helps reduce false-positive results by examining and compensating for many of the effects of non-specific binding which improves specificity.

The clinical lab version joins the previously FDA-cleared and CLIA- waived BD Veritor System for Rapid Detection of Flu A+B. This assay for Rapid Detection of Flu A+B on the BD Veritor System represents the first of many planned assays on this new platform.

For more information on the BD Veritor System, please visit www.bd.com/ds/veritorsystem.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Jamie Yacco
Public Relations
+1-
201-847-4796
Jamie_Yacco@bd.com

SOURCE BD-Becton Dickinson



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES